Kenneth Song
Founder & former CEO
radiopharmaceuticalsnuclear medicineoncology
Details
- ●Modalities: radiopharmaceuticals (actinium-225 targeted alpha therapy)
- ●Therapeutic areas: oncology
- ●Key targets: SSTR2 (somatostatin receptor 2), PSMA, DLL3, GPC3
- ●Indications: gastroenteropancreatic neuroendocrine tumors, small cell lung cancer, metastatic castration-resistant prostate cancer, hepatocellular carcinoma
- ●Funding: $4.1B (acquisition by BMS, 2024)
Partners & investors
- Bristol Myers Squibb (acquirer)· Investor
- Column Group (pre-acquisition)· Investor
- Venrock (pre-acquisition)· Investor
- RA Capital Management (pre-acquisition)· Investor
Key considerations
- ●AI tools in use: Proprietary Ac-225 manufacturing platform, Chelator chemistry optimization, Dosimetry modeling for alpha emitters
- ●Differentiated actinium-225 platform (vs lutetium-177 competitors)
- ●Built state-of-the-art radiopharmaceutical manufacturing capabilities
- ●IND engine designed for rapid generation of new radioligand candidates
Pipeline
- Preclinical1
- Phase 11
- Phase 31
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)
Key people
Simon Lowry
Head of Radiopharmaceutical Development (BMS)
radioligand therapyclinical oncologytargeted alpha therapy